Pinealon

Plain-English version: Pinealon is a very short synthetic peptide — just three amino acids joined together. Chemists abbreviate its sequence as EDR, or spelled out, Glu-Asp-Arg (glutamic acid–aspartic acid–arginine). Because it is so small, researchers hypothesize it can slip inside cells and even reach the brain, which is the reason it is studied for neuroprotection ("protecting nerve cells").

Pinealon comes from the laboratory of Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology. That group has spent decades on a family of short "bioregulatory" peptides — including Epitalon and Thymalin — each designed to influence a particular tissue. Pinealon is described as related to a peptide preparation of the pineal gland/brain, and the group's core hypothesis is that these tiny peptides can bind DNA and regulate which genes a cell switches on.^[3]

The credibility caveat, stated up front: that gene-regulation hypothesis is interesting but remains exactly that — a hypothesis argued mostly in review papers, not a mechanism proven in humans. Just as important, every primary study we could verify for Pinealon comes from the Khavinson group or affiliated Russian labs, and we found no independent replication by an outside laboratory and no verified controlled human clinical trial. Pinealon is not FDA-approved for anything, is not an approved drug, and is not a recognized dietary-supplement ingredient — it is sold only as a "research use only" compound. For the wider legal picture, see Are Peptides Legal?

Takeaway first: the clearest, best-supported thing Pinealon does — in a dish — is calm down oxidative stress inside cells and keep them from dying. Everything beyond that (gene regulation, effects on the whole brain) is proposed mechanism drawn from cell and animal work and review-paper theory, not proven human biology. Here is what the verified research actually shows, and where it stops.

1. Lowering reactive oxygen species (best-supported effect)

"Reactive oxygen species" (ROS) are unstable molecules that build up when a cell is stressed and damage it from the inside — a process called oxidative stress. In cell-culture experiments using cerebellar granule cells (a type of brain neuron), PC12 cells, and neutrophils, Pinealon restricted ROS build-up in a dose-dependent way (more peptide, less ROS) and reduced necrotic cell death — cells dying and rupturing.^[1] That antioxidant, anti-cell-death effect is Pinealon's single most concrete finding. Evidence level: cell culture only — not animals, not humans.

2. ERK/MAPK signaling and the cell cycle

In the same cell study, the protection came alongside a delayed activation of ERK1/2 — part of the MAPK signaling pathway cells use to decide whether to grow, repair, or die — and changes in the cell cycle that favored survival and proliferation.^[1] In plain terms, Pinealon appears to nudge the cell's internal "repair-or-die" switch toward repair. Evidence level: cell culture.

3. Proposed gene-expression and epigenetic regulation (review-level theory)

The Khavinson group's central hypothesis is that EDR is small enough to enter a cell, reach the nucleus, and bind DNA or the histone proteins DNA wraps around — thereby changing which genes are active. Their review proposes that EDR upregulates antioxidant-enzyme genes (SOD2, GPX1), turns down pro-death genes (caspase-3, p53), boosts PPARA/PPARG, and even influences serotonin synthesis.^[3] A companion mouse study reported that EDR has binding sites in the promoter regions of genes such as CASP3, SOD2, GAP43, APOE, PPARA, and PPARG.^[4] Evidence level: a hypothesis paper plus mouse data — not established, and not shown in humans. Treat this as the group's proposed explanation, not settled science.

What we do NOT know

There is no confirmed human receptor or target for Pinealon, no established human pharmacokinetics (how it is absorbed, distributed, and cleared in people), and no human dose-response data. The mechanisms above are real published findings — but they are almost entirely from rodents and cell cultures produced by a single research program, and mechanism in a dish does not guarantee benefit in a person.

How to read this section: for each area we give the plain-English claim, the proposed mechanism, the population actually studied, the observed effect, and the limitation. Every result below is from cells, rats, or mice, and every one comes from the Khavinson group. That does not make the findings worthless — it makes them preliminary and unreplicated. There are no human efficacy data.

Protecting brain cells from oxidative stress

Claim: may shield neurons from oxidative damage. Mechanism: lowering ROS build-up and blocking necrotic cell death, alongside delayed ERK1/2 signaling. Population: cerebellar granule cells, PC12 cells, and neutrophils in culture. Effect: Pinealon dose-dependently restricted ROS and reduced necrotic cell death under oxidative stress.^[1] Limitation: this is cell-culture work only — no standardized effect size, no animal or human confirmation of a clinical benefit.

Learning and memory (animal injury model)

Claim: may support learning and memory when the developing brain is injured. Mechanism: neuroprotection plus reduced oxidative damage to neurons. Population: rat offspring whose mothers had methionine-induced hyperhomocysteinemia (a pregnancy stressor that harms the fetal brain), with Pinealon given to the mothers. Effect: the offspring showed improved spatial navigation and learning and had cerebellar neurons more resistant to oxidative stress (less ROS, fewer necrotic cells).^[2] Limitation: a single-lab rat model of a specific prenatal injury with a small sample; effect size was not reported as a standardized metric, and none of this establishes a memory benefit in healthy humans. Cognitive claims should be read against this narrow context, which is why the cognitive-enhancement interest here runs well ahead of the evidence.

Neuroprotection in an Alzheimer's mouse model

Claim: may protect neural connections in neurodegeneration. Mechanism: proposed epigenetic gene regulation (binding promoter regions of neuroprotective genes) plus antioxidant support. Population: 5xFAD transgenic mice, a standard Alzheimer's-disease model, given daily intraperitoneal (into-the-abdomen) peptide. Effect: EDR (Pinealon) — dosed at 400 µg/kg/day by intraperitoneal injection, once daily for about 2 months (the companion peptide KED was given on the same protocol) — prevented dendritic-spine loss, the loss of the tiny connection points between neurons, and supported neuroplasticity.^[4] Limitation: a transgenic mouse model, single lab; preventing spine loss in mice is not the same as slowing dementia in people, and no human data exist.

The honest bottom line on "benefits"

• No human clinical trials could be verified. Human pharmacokinetics, effective doses, and outcomes are unknown.
• Research is highly concentrated. Every verified study comes from the Khavinson group or affiliated Russian labs, with no independent Western replication.
• Publication bias means positive preclinical results are more likely to reach print than null ones.
• Anecdotes are not data. Enthusiastic user reports cannot substitute for controlled trials, and none exist here.

Read this first: there is no clinically validated human dose for Pinealon, because we could not verify a single controlled human trial. The doses that circulate online are extrapolated from animal studies and vendor labeling, not from human data. We describe the research context and the arithmetic here for completeness and harm reduction — not as medical guidance or a recommendation to self-administer an unapproved compound.

What the animal studies actually used

The verified in-vivo work gives dosing in per-kilogram animal terms, not human doses. In the Alzheimer's mouse study, EDR (Pinealon) was administered at 400 µg/kg/day by intraperitoneal injection, once daily for about 2 months (the companion peptide KED was dosed on the same protocol).^[4] In the rat prenatal-injury study, Pinealon was given to the pregnant dams during gestation.^[2] These are experimental animal protocols — they do not translate directly into a safe or effective human dose.

Commonly cited research protocols (extrapolated, not validated)

Route	Commonly cited amount	Frequency	Note
Subcutaneous	1–10 mg total (vial-based)	Once daily	Figures come from vendor labeling, not trials
Intranasal	Per product labeling	Once daily	Proposed to aid brain delivery; unverified
Oral (capsule)	Per product labeling	Per label	Sold in some markets; no verified trial support

Important: you will see Pinealon vials sold in a range of strengths and hear a range of "protocols." None of these are backed by a verified human study. Treat every number as an unvalidated convention.

Reconstitution math, with a worked example

Injectable Pinealon ships as a lyophilized (freeze-dried) powder that must be mixed with bacteriostatic water before use. The core formula is the same for every peptide:

Concentration (mg/mL) = vial amount (mg) ÷ water added (mL)

Worked example: take a 10 mg vial and add 2 mL of bacteriostatic water. That gives 10 ÷ 2 = 5 mg/mL, i.e. 5,000 mcg per mL. If a protocol called for a 500 mcg dose: 500 ÷ 5,000 = 0.10 mL, which is 10 units on a standard 100-unit insulin syringe. A 1,000 mcg (1 mg) dose would be 0.20 mL, or 20 units.

Vial	BAC water	Concentration	500 mcg	1 mg
10 mg	2 mL	5.0 mg/mL	0.10 mL (10 units)	0.20 mL (20 units)
10 mg	1 mL	10.0 mg/mL	0.05 mL (5 units)	0.10 mL (10 units)
5 mg	1 mL	5.0 mg/mL	0.10 mL (10 units)	0.20 mL (20 units)

Preparation steps: wipe the vial stopper with alcohol; draw the water; inject it slowly down the inside wall rather than blasting the powder; swirl gently (do not shake) until fully dissolved; label the vial with the date and concentration. Use the peptide calculator and bacteriostatic water calculator to check volumes, and the reconstitution guide for a full walkthrough.

Cycle length, timing, and storage

• Cycle: Khavinson-style protocols are conventionally run as short courses (often 10–20 days) that may be repeated after a break. These durations come from convention, not verified human trials.
• Timing: some users favor evening dosing to align with pineal/circadian activity, but there is no trial evidence that timing changes outcomes.
• Storage: keep lyophilized vials frozen (about -20°C) for long-term or refrigerated (2–8°C) short-term; refrigerate reconstituted solution and use within a few weeks; protect from light and heat. See the peptide storage guide.

Again: none of the above is a recommendation to self-administer. It describes how research and vendor doses are structured, so a reader can evaluate claims critically.

Straight talk: published Khavinson-group studies report no significant adverse effects, but that reassurance rests entirely on cell and animal work from one research program — there are no controlled human safety trials for Pinealon that we could verify. "No adverse effects reported" is not the same as "proven safe in people." And for any unregulated research peptide, product quality is a real and separate hazard: impurities in a poorly made vial can cause problems that get blamed on the peptide itself.

Reported side effects

Effect	Frequency	Severity	Notes
Injection-site redness/irritation	Occasional	Mild	Transient; typical of subcutaneous injections
Significant adverse events	None reported	—	In published preclinical studies only; no human trials

Note on the "well-tolerated" claim you will see repeated online: it traces back to preclinical, single-lab data. Treat it as unconfirmed in humans rather than an established safety fact.

Who should avoid it

• Pregnancy and breastfeeding: no human safety data — avoid. (Note the rat evidence involves dosing pregnant animals in an experiment; that is not endorsement of human use in pregnancy.)
• Known hypersensitivity to the peptide or vial components.
• Anyone on a related regimen (e.g., melatonin or other neuroactive agents): interactions have not been studied; a theoretical concern, not an established one.

The limitations you must keep in mind

• All safety data are preclinical (cells and rodents) and come from a single research group, with no independent replication.
• No verified human trials means human pharmacokinetics, drug interactions, and long-term safety are unknown.
• The gene-regulation theory underlying Pinealon remains controversial in mainstream pharmacology.
• Contaminants from low-quality product are a real, separate risk.

For broader context, see Are Peptides Safe? and Peptide Side Effects.

Why this section matters: Pinealon is an unregulated research compound, so purity and identity vary widely between suppliers. For an unproven peptide, contamination is arguably a bigger practical risk than the peptide itself. Learning to read a Certificate of Analysis (COA) is the single most useful skill here.

What a credible product should show

• Third-party COA: independent HPLC purity testing (look for ≥98%) plus mass-spectrometry identity confirming the expected molecular weight of the EDR (Glu-Asp-Arg) tripeptide.
• Batch-specific results: the COA should reference the exact lot you are buying, not a generic sample.
• Endotoxin testing (LAL): important for anything intended to be injected.
• Proper form and packaging: lyophilized powder in a sealed, light-protected vial.

Red flags

• No COA, or a COA from the seller rather than an independent lab
• Pre-mixed liquid "ready to use" peptide (shorter shelf life, contamination risk)
• Prices far below the market
• Explicit human-use or medical claims, which signal a non-compliant, higher-risk vendor

Legal and regulatory status (2026)

• Not FDA-approved for any use, and not an approved drug.
• Not a recognized dietary-supplement ingredient — it is sold strictly as a "research use only" compound.
• No verified US clinical trial or approval: no NDA/BLA and no registered human RCT for Pinealon could be verified.
• Not a controlled substance: Pinealon is not DEA-scheduled.

For the complete legal picture, read Are Peptides Legal?

How Pinealon compares to related peptides

Pinealon is usually discussed next to other Khavinson peptides. None of these comparisons are backed by head-to-head human trials — they contrast proposed roles and the preclinical literature.

Factor	Pinealon (EDR)	Epitalon
Sequence	Glu-Asp-Arg (3 amino acids)	Ala-Glu-Asp-Gly (4 amino acids)
Main research focus	Neuroprotection, antioxidant/anti-cell-death in brain cells	Telomerase activation, aging, circadian/sleep
Evidence level	Preclinical only, single lab	Preclinical plus limited early human reports, single lab

Anyone weighing Pinealon should read the Epitalon guide for the closest comparison, and the cognitive-enhancement goal page for peptides with a stronger evidence base.